On September 28, 2023, Danish-based Novo Nordisk Region Europe declared that it had exceeded the thresholds of 90% of the capital and voting rights in Biocorp Production, and held 4,317,044 Biocorp Production shares, representing 97.84% of the Company's capital and at least 97.47% of its voting rights.

This threshold crossing results from the acquisition of Biocorp Production shares as part of the public offer initiated by the declaring party4.

Copyright (c) 2023 CercleFinance.com. All rights reserved.